Literature DB >> 3002166

Relapsed Wilms' tumor. Factors affecting survival and cure.

J A Wilimas, J Champion, E C Douglass, D Parham, E Hammond, B Webber.   

Abstract

To identify factors contributing to extended survival among patients with relapsed Wilms' tumor, we assessed 10 clinical and biologic variables thought to have predictive value. With a median follow-up of 6 years, 32 (20%) of 156 patients who achieved complete remission have relapsed. Twenty-four have died with recurrent tumor, and eight are surviving for 2 to 12 years from diagnosis. Only time to relapse, or length of initial complete remission, had a significant influence on survival. Of 11 patients with complete remissions lasting longer than 12 months, six have died--compared with seven of 10 having remissions of 6 to 12 months and 11 of 11 with shorter remissions (p = 0.014). Surgery alone was the curative therapy in three of the eight surviving patients. Until more effective chemotherapy regimens are developed, an aggressive surgical approach may be indicated in selected patients with relapsed Wilms' tumor.

Entities:  

Mesh:

Year:  1985        PMID: 3002166

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  1 in total

1.  Multidrug resistance transporter profile reveals MDR3 as a marker for stratification of blastemal Wilms tumour patients.

Authors:  Lourdes Hontecillas-Prieto; Daniel J Garcia-Dominguez; Diego Pascual Vaca; Rosa Garcia-Mejias; David Marcilla; Gema L Ramirez-Villar; Carmen Saez; Enrique de Álava
Journal:  Oncotarget       Date:  2017-02-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.